An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving ...

Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching among patients with psoriasis ...

As we previously reported, JAMP sought leave to commence an application against Janssen under the abuse of dominance ...

Tambe said the company, a subsidiary of the Bengaluru-based Biocon Ltd, has five products in the pipeline for launch in the ...

The Union Budget 2025-26 introduces key healthcare measures, including the exemption of 36 life-saving drugs from Basic ...

UBS forecasts that Sandoz will likely achieve the lower end of its 24-26% core EBITDA margin target by 2028. To reach the ...

The IRA measure is a good first step, but some are looking even further ahead to GLP-1 price drops to increase access.

TORONTO, Jan. 8, 2025 /CNW/ - Fresenius Kabi Canada proudly announces the recent Health Canada Notice of Compliance (NOC) for Otulfi TM, an ustekinumab biosimilar indicated for Crohn's disease ...

Celltrion, a major South Korean biopharmaceutical firm, on Friday said its new biosimilar for an autoimmune disease treatment has received approval from the US Food and Drug Administration (FDA). The ...

Celltrion Inc.'s autoimmune disease treatment, SteQeyma, has been launched in five major European nations, the Korean company ...

The J&J deal would be the biggest biotech deal in over a year and will add treatments for disorders of the central nervous ...